Viking Therapeutics, Inc.
Viking Therapeutics, Inc. (VKTX): 10 pipeline candidates · 2 upcoming catalysts · ~15 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.3 months
D/E 0.21 · 0% dilution
Lead: Phase 3
10 candidates
2 upcoming, next in ~30d
1 buy · 13 sells (180d)
A transparent, data-derived signal for Viking Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.5B
Cash
$118.1M
Quarterly Burn
$114.0M
Runway
15.3 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| DACRA (dual amylin and calcitonin receptor agonists) | Preclinical |
| DGAT-1 inhibitors | Preclinical |
| Dual Amylin and Calcitonin Receptor Agonist (DACRA) program | Preclinical |
| Orally available EPOR agonists | Preclinical |
| VK0214 | Phase 1 |
| VK0612 | Phase 2 |
| VK2375 | Phase 3 |
| VK2735 | Phase 3 |
| VK2809 | Phase 2 |
| VK5211 | Phase 2 |
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
413
Total value held
$2.86B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 10,025,004 | $326.2M |
| blackrock, inc. | 6,880,290 | $223.9M |
| fmr llc | 6,024,753 | $196.0M |
| susquehanna international group, llp | 4,820,309 | $156.9M |
| vanguard portfolio management llc | 4,464,298 | $145.3M |
| two sigma investments, lp | 4,432,142 | $144.2M |
| state street corp | 4,395,557 | $143.0M |
| raymond james financial inc | 2,075,403 | $113.5M |
| morgan stanley | 3,013,928 | $98.1M |
| citadel advisors llc | 2,615,121 | $85.1M |
Showing top 10 of 413 institutional holders of Viking Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Viking Therapeutics, Inc.'s pipeline?
Viking Therapeutics, Inc. (VKTX) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Viking Therapeutics, Inc.'s lead drug candidate?
Viking Therapeutics, Inc.'s most advanced tracked candidate is DACRA (dual amylin and calcitonin receptor agonists) (Preclinical) for obesity.
What is Viking Therapeutics, Inc.'s next catalyst?
Viking Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DUEXIS" — expected July 18, 2026.
What is Viking Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Viking Therapeutics, Inc. has approximately 15.3 months of cash runway.
What is Viking Therapeutics, Inc.'s market capitalization?
Viking Therapeutics, Inc.'s market capitalization is approximately $3.5B.
Get the full picture on Viking Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.